Report of the Joint Allocation Taskforce (JAT) on the distribution of COVAX Facility secured vaccines: 15 March 2021

15 March 2021
 | Meeting report
Download (606.7 kB)

Overview

The purpose of this document is to provide supportive data and a data driven proposal for the distribution to eligible COVAX Facility p articipant s of BNT162b2/COMIRNATY Tozinameran ( Pfizer vaccine, which is among the COVAX Facility secured vaccines. This product has received a WHO Emergency Use Listing ( and has already been allocated in a “first wave” distribution of small allocations to 18 COVAX Facility participants. This report is intended to facilitate decision making on further allocation b y the Independent Allocation of Vaccine s Group (IAVG).

 

 

WHO Team
Independent Allocation of Vaccines Group
Number of pages
6